ATE373644T1 - N-substituierte 3-hydroxy-4-pyridinone und diese enthaltende pharmazeutika - Google Patents

N-substituierte 3-hydroxy-4-pyridinone und diese enthaltende pharmazeutika

Info

Publication number
ATE373644T1
ATE373644T1 AT03737635T AT03737635T ATE373644T1 AT E373644 T1 ATE373644 T1 AT E373644T1 AT 03737635 T AT03737635 T AT 03737635T AT 03737635 T AT03737635 T AT 03737635T AT E373644 T1 ATE373644 T1 AT E373644T1
Authority
AT
Austria
Prior art keywords
pyridinones
hydroxy
substituted
metal chelates
containing same
Prior art date
Application number
AT03737635T
Other languages
English (en)
Inventor
Shuang Liu
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE373644T1 publication Critical patent/ATE373644T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0474Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0476Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from monodendate ligands, e.g. sestamibi
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03737635T 2002-02-05 2003-02-05 N-substituierte 3-hydroxy-4-pyridinone und diese enthaltende pharmazeutika ATE373644T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35433902P 2002-02-05 2002-02-05

Publications (1)

Publication Number Publication Date
ATE373644T1 true ATE373644T1 (de) 2007-10-15

Family

ID=27734359

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03737635T ATE373644T1 (de) 2002-02-05 2003-02-05 N-substituierte 3-hydroxy-4-pyridinone und diese enthaltende pharmazeutika

Country Status (8)

Country Link
US (2) US6825204B2 (de)
EP (1) EP1474396B9 (de)
JP (1) JP2005516987A (de)
AT (1) ATE373644T1 (de)
AU (1) AU2003210850A1 (de)
DE (1) DE60316410T2 (de)
PL (1) PL371746A1 (de)
WO (1) WO2003065991A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110399A2 (en) * 2004-04-29 2005-11-24 The Regents Of The University Of California Zinc-binding groups for metalloprotein inhibitors
US20100166662A1 (en) * 2006-03-27 2010-07-01 The University Of Chicago Magnetic resonance imaging method using vanadyl-based contrast agents
US8236783B2 (en) * 2006-08-15 2012-08-07 Duke University ROS-sensitive iron chelators and methods of using the same
WO2008100907A2 (en) 2007-02-13 2008-08-21 Board Of Supervisors Of Louisiana State University And Argricultural And Mechanical College Fluoride-releasing compositions
US8916163B1 (en) 2007-12-21 2014-12-23 Vanderbilt University Method for treating microbial infections
EP2291084A4 (de) 2008-05-20 2012-04-25 Neurogesx Inc Carbonat-prodrugs und verfahren zu ihrer verwendung
JP5757864B2 (ja) 2008-05-20 2015-08-05 ニューロジェシックス, インコーポレイテッド 水溶性アセトアミノフェン類似体
EP3024936B1 (de) 2013-07-25 2019-09-04 Exicure, Inc. Sphärische nukleinsäurebasierte konstrukte als immunstimulatoren für prophylaktische und therapeutische verwendung
DE102013217034A1 (de) 2013-08-27 2015-03-05 Henkel Ag & Co. Kgaa Wasch- und Reinigungsmittel mit verbesserter Leistung
CN107074767A (zh) * 2014-08-20 2017-08-18 西北大学 用于反义基因调节的生物相容的无限配位聚合物纳米颗粒–核酸缀合物
CN111995567B (zh) * 2020-07-24 2022-11-25 浙江工业大学 具潜在多靶点抗ad活性的甲酰胺吡啶酮类铁螯合剂衍生物及其制备方法与应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2136807A (en) 1934-12-17 1938-11-15 John S Skelly Side retort stoker
AU6621586A (en) 1985-11-18 1987-06-02 University Of Texas System, The Polychelating agents for image and spectral enhancement (and spectral shift)
US4908371A (en) 1987-11-10 1990-03-13 Ciba-Geigy Corporation Esterified hydroxy dihydropyridinones for treating diseases associated with trivalent metal ion overload
WO1989009211A1 (en) 1988-03-31 1989-10-05 The Royal Free Hospital School Of Medicine Process for producing pyrid-4-ones
US5087440A (en) 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
WO1991012822A1 (de) 1990-03-02 1991-09-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Zubereitungen für die mr-diagnostik
US5143716A (en) 1991-02-01 1992-09-01 Unger Evan C Phosphorylated sugar alcohols, Mono- and Di-Saccharides as contrast agents for use in magnetic resonance imaging of the gastrointestinal region
US5866563A (en) 1991-09-30 1999-02-02 The University Of British Columbia Vanadium compositions
US5527790A (en) 1991-09-30 1996-06-18 The University Of British Columbia Bis(maltolato)oxovanadium compositions for the treatment of elevated blood sugar
US5336482A (en) * 1991-12-05 1994-08-09 The Du Pont Merck Pharmaceutical Company Technetium-99m complexes with N-substituted 3-hydroxy-4-pyridinones
GB9209078D0 (en) 1992-04-27 1992-06-10 Hider Robert C Pharmaceutical compositions
GB9217099D0 (en) 1992-08-12 1992-09-23 British Tech Group Pharmaceutical compositions
JPH07179474A (ja) * 1993-10-05 1995-07-18 Takeda Chem Ind Ltd 新規セフェム化合物、その製造法およびその抗菌組成物
US5565491A (en) 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
GB9416768D0 (en) 1994-08-18 1994-10-12 Nycomed Innovation Ab Compositions
WO1996005867A2 (en) 1994-08-18 1996-02-29 Nycomed Imaging A/S Compositions
US5789426A (en) 1995-01-20 1998-08-04 Cornell Research Foundation, Inc. Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
US6046219A (en) * 1995-01-20 2000-04-04 Cornell Research Foundation, Inc. Method for the treatment of conditions mediated by collagen formation together with cell proliferation by application of inhibitors of protein hydroxylation
US5849587A (en) * 1995-06-09 1998-12-15 Cornell Research Foundation, Inc. Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells
DK81095A (da) 1995-07-11 1997-01-12 Henrik S Thomsen Peroralt MR-kontraststof til lever og øvre tarmkanal
ES2244967T3 (es) 1995-09-29 2005-12-16 Novartis Ag Nuevas hidroxipiridinonas.
FR2750699B1 (fr) 1996-07-05 1998-12-04 Univ Picardie Procede de synthese regiospecifique de nouveaux derives 3-hydroxypydirin-4(1h)-ones a partir d'aminomonosaccharides ou d'aminoitols. produits obtenus par ce procede et leurs applications
US6232340B1 (en) 1997-04-24 2001-05-15 Angiotech Pharmaceuticals, Inc. Vanadium complexes and derivatives thereof and methods related thereto
GB9711093D0 (en) 1997-05-29 1997-07-23 British Tech Group Novel orally active iron (III) chelators
GB9723078D0 (en) 1997-10-31 1998-01-07 Cerebrus Ltd Chemical compounds
US6248579B1 (en) 1998-02-13 2001-06-19 Pfizer Inc Streptomyces avermitilis gene directing the ratio of B2:B1 avermectins
AU5613999A (en) 1998-09-18 2000-04-10 University Of British Columbia, The Pharmaceutical compositions of vanadium biguanide complexes and their use
ATE285221T1 (de) 1998-09-23 2005-01-15 Unilever Nv Orale zusammensetzung mit verbessertem bleichendem effekt
WO2000024730A1 (en) 1998-10-28 2000-05-04 The University Of British Columbia Organic vanadium(iii) complexes and their use
US5980863A (en) 1998-11-02 1999-11-09 Eagle Vision Pharmaceutical Corporation Manganese compositions and methods for MRI
EP1006112A1 (de) 1998-12-01 2000-06-07 Cerebrus Pharmaceuticals Limited 3-Hydroxy-2(1H)-pyridinon- oder 3-hydroxy-4(1H)-pyridinon- Derivate verwendbar als reaktive Sauerstoffspezies-Fänger (ROS)
EP1006108A1 (de) 1998-12-01 2000-06-07 Cerebrus Pharmaceuticals Limited 3-Hydroxy-2(1H)-pyridinon- oder 3-hydroxy-4(1H)-pyridinon- Derivate verwendbar als reaktive Sauerstoffspezies-Fänger (ROS)
GB2345058A (en) 1998-12-01 2000-06-28 Cerebrus Pharm Ltd Hydroxypyridone compounds useful in the treatment of oxidative damage to the central nervous system
US6294152B1 (en) * 1999-01-11 2001-09-25 The University Of Toledo Iron(III) complexes as contrast agents for image enhancement in magnetic resonance imaging
US6323340B1 (en) 1999-07-30 2001-11-27 Nippon Shobukai Co., Ltd. Phthalocyanine compound, method for production thereof, and near infrared absorption dye using the compound
NL1012825C2 (nl) 1999-08-13 2001-02-23 Faculteit Geneeskunde Universi Farmaceuticum voor de behandeling van virale infecties in het bijzonder van het humane immunodeficiency virus (HIV).

Also Published As

Publication number Publication date
DE60316410D1 (de) 2007-10-31
US20040176326A1 (en) 2004-09-09
US20030170174A1 (en) 2003-09-11
AU2003210850A1 (en) 2003-09-02
EP1474396A2 (de) 2004-11-10
WO2003065991A3 (en) 2003-12-31
JP2005516987A (ja) 2005-06-09
EP1474396A4 (de) 2006-01-18
WO2003065991A2 (en) 2003-08-14
US6825204B2 (en) 2004-11-30
EP1474396B1 (de) 2007-09-19
EP1474396B9 (de) 2008-07-09
DE60316410T2 (de) 2008-06-19
US6932960B2 (en) 2005-08-23
PL371746A1 (en) 2005-06-27
AU2003210850A8 (en) 2003-09-02

Similar Documents

Publication Publication Date Title
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
MY142589A (en) Benzimidazole derivatives : preparation and pharmaceutical applications
EA200500354A1 (ru) Новые оксазольные и тиазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
EA200600078A1 (ru) Способы и композиции для лечения амилоидных заболеваний
BRPI0418251B8 (pt) fosfonatos, monofosfonamidatos, bisfosfonamidatos, e, composição farmacêutica os compreendendo
BR0113838A (pt) Derivados de n-fenil-2-pirimidina-amina
DE60003863D1 (de) Dioxocyclopentylhydroxamsäure
EA200700489A1 (ru) Новые бензоконденсированные гетероарилсульфамидные производные, полезные в качестве противоконвульсивных средств
EA200500286A1 (ru) Новые изотиазольные и изоксазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)
DE60325498D1 (de) 1-acyl-pyrrolidin-derivate für die behandlung von viralen infektionen
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
ATE388708T1 (de) Piperazinderivate und anwendungsverfahren
EA200400086A1 (ru) Новые производные оксазолидинонов в качестве антибактериальных агентов
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
DE602004007268D1 (de) CYCLOALKYLSULFANYL-SUBSTITUIERTE BENZOiBöTHIOPHENE ALS THERAPEUTISCHE MITTEL
ATE405568T1 (de) Cytotoxische mittel
ATE373644T1 (de) N-substituierte 3-hydroxy-4-pyridinone und diese enthaltende pharmazeutika
EA200501821A1 (ru) Фармацевтическая комбинация, содержащая модафинил и другой лекарственный препарат
SE0302304D0 (sv) Novel compounds
ITMI20021881A1 (it) Composizioni farmaceutiche per il trattamento di infezioni da patogeni dell'apparato urinario.
ATE410415T1 (de) Neue verbindungen
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen
DE60208541D1 (de) Antibakterielle mittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties